Definium Therapeutics, Inc. - 10-Q Filing
Definium Therapeutics filed its 10-Q for the quarter ended March 31, 2026, disclosing financial results and operational updates. The company reported a net loss of $18.4 million for the first quarter of 2026, compared to a net loss of $15.2 million in the same period in 2025. Total operating expenses were $18.4 million, primarily driven by research and development and general and administrative costs. The filing also outlined updates to financing arrangements, including amendments to term loans with K2 Health Ventures LLC.
Tickers: $MNMD